Ketospray (Ketoprofen)

Ketoprofen works by non‑selectively inhibiting the cyclooxygenase‑1 (COX‑1) and cyclooxygenase‑2 (COX‑2) enzymes, which are essential for converting arachidonic acid into prostaglandins. By reducing prostaglandin production, ketoprofen diminishes inflammation, pain signaling, and fever, leading to symptom relief where it is applied.

The appropriate amount of Ketospray to apply, as well as the frequency of application, is determined by the prescribing healthcare professional based on the individual’s condition, severity, and treatment response. Patients should follow the prescriber’s instructions and not exceed the recommended number of applications.

Safety data for topical ketoprofen during pregnancy and lactation are limited. Because the product’s pregnancy category is unknown, it should only be used if the potential benefit outweighs any possible risk, and only after consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the Ketospray product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ketospray contains ketoprofen, a potent NSAID with both COX‑1 and COX‑2 inhibition, offering strong anti‑inflammatory and analgesic activity. Compared with some other topical NSAIDs that may have selective COX‑2 inhibition, ketoprofen provides broader prostaglandin suppression, which can translate into effective relief for a wider range of inflammatory conditions.

Ketospray should be stored at room temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the container tightly closed when not in use, and avoid exposing the product to extreme temperatures or humidity to maintain its stability and efficacy.

The spray is applied to clean, intact skin at the affected area. The prescriber will specify the number of sprays per application and the maximum frequency (often 2‑4 times daily). After spraying, allow the medication to dry before covering the area with clothing or bandages.

Serious adverse reactions, although rare, include severe allergic responses such as facial swelling, difficulty breathing, or anaphylaxis, as well as life‑threatening skin conditions like Stevens‑Johnson syndrome or toxic epidermal necrolysis. Immediate medical attention is required if any of these symptoms develop.

Ketospray should be avoided in individuals with known hypersensitivity to ketoprofen or any other NSAIDs, in patients with active skin infections or open wounds at the intended site of application, and in those who have experienced severe cutaneous adverse reactions to NSAIDs in the past.